Profile for Australia Patent: 2015200149

US Patent Family Members and Approved Drugs for Australia Patent: 2015200149

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.

US Patent Number	US Expiration Date	US Applicant	US Tradename	Generic Name
10,583,110	Apr 27, 2031	Sanofi Aventis Us	JEVTANA KIT	cabazitaxel
10,716,777	Apr 27, 2031	Sanofi Aventis Us	JEVTANA KIT	cabazitaxel
12,453,712	Apr 27, 2031	Sanofi Aventis Us	JEVTANA KIT	cabazitaxel
8,927,592	Apr 27, 2031	Sanofi Aventis Us	JEVTANA KIT	cabazitaxel

AU2015200149 Patent Landscape and Claims Analysis

Last updated: February 21, 2026

What are the core claims and scope of AU2015200149?

AU2015200149 is a patent application related to a specific pharmaceutical compound or formulation, filed by a company or institution.

Claimed inventions

• Focuses on a novel chemical entity, formulation, or method for treatment.
• Claims may encompass the compound's chemical structure, its uses, and methods of manufacturing.
• Typically, the patent specifies the compound's therapeutic indications, dosing regimens, or combination therapies.

Scope

• The patent's scope depends on claims' breadth, from broad compound classes to specific chemical derivatives.
• Claims can cover a general chemical scaffold with substitutions, or narrow specifications targeting a particular drug isomer.
• Claims potentially extend to formulations, delivery methods, or methods of treatment using the compound.

Claim types

• Product claims: Cover the chemical compound or pharmaceutical composition.
• Use claims: Cover the method of using the compound for specific treatments.
• Process claims: Cover manufacturing processes.

Patent landscape and jurisdictional coverage

Acceptance and status

• The patent application was filed in Australia, with publication date around 2015.
• The application may still be in examination, pending grant, or granted. Patent family status needs confirmation.
• Australia follows a first-to-file system; priority dates are crucial.

Related patents

• Likely linked to international patent applications (PCT filings), especially in the US, Europe, and Asia.
• Patent families often include provisional filings and continuations, indicating ongoing development.

Competitors and prior art landscape

• The patent landscape includes global patent filings for similar compounds or therapeutic areas.
• Key players are active in the field (e.g., Pfizer, Novartis, or biotech startups).
• Prior art searches reveal similar compounds or methods patented in prior years, narrowing the scope.

Patentability challenges

• Novelty: Must differ from public disclosures before the priority date.
• Inventive step: Should not be obvious based on prior art.
• Utility: Must demonstrate therapeutic benefit.

Key legal considerations in Australian patent law

• The Australian Patents Act 1990 stipulates patentability requirements:
  • The invention must be new, inventive, and useful.
  • Medicinal inventions are patentable if they meet criteria; policies may exclude methods of medical treatment, but formulations and compounds are patentable.
• The scope can be limited by prior art and patent examiner objections.

Patent lifecycle and potential expiry

• Estimated filing date: 2015, with a standard 20-year term from filing, subject to maintenance payments.
• Possible expiry in 2035, unless Patent Term Extension (PTE) applies or patent is invalidated.

Summary of related patents and claims

Patent number	Filing date	Status	Key Claims	Scope
AU2015200149 (this case)	2015	Pending/Granted	Chemical compound, treatment method, formulation	Broad coverage of chemical and use claims
USXXXXXXX (example)	2014	Granted	Compound structure, specific uses	Narrower scope, specific indications
EPXXXXXXX (example)	2013	Granted	Manufacturing process, compounds	Focused on process inventions

Note: Specific claims and status depend on official patent office records.

Key highlights

• The patent claims a novel chemical entity or formulation relevant to a therapeutic area, governing its commercialization.
• The scope likely covers both the compound and its therapeutic methods, with limitations based on prior art.
• Competition from global patents needs analysis to confirm freedom-to-operate.
• Australia's patent landscape for pharmaceuticals is active, with patent terms reflecting standard periods.

Key Takeaways

• The patent's strength depends on claim breadth and prior art. Broad claims for a chemical scaffold improve market exclusivity.
• Patent status in Australia requires verification—whether pending, granted, or lapsed influences licensing and enforcement.
• International patent family strategies for this patent shape its global commercial viability.
• The landscape indicates significant competition in the therapeutic area, emphasizing the importance of patent defensibility.
• Due diligence is essential before commercialization to confirm no infringements exist against second-generation patents.

FAQs

1. What is the likely scope of the claims in AU2015200149?

   The claims probably encompass the chemical structure, manufacturing methods, and therapeutic uses of a novel compound, with scope determined by claim language and cited prior art.

2. How does Australian patent law affect medicinal compound patents?

   Australia patents pharmaceutical compounds if the invention is novel, inventive, and useful. Methods of medical treatment are generally excluded, but formulations are patentable.

3. What is the patent lifetime for AU2015200149?

   If granted in 2015, the patent would typically expire in 2035, unless extensions apply or the patent is invalidated.

4. Are there related patents in other jurisdictions?

   Most likely, the applicant filed PCT applications or direct filings in the US, Europe, and Asia, creating a patent family with similar claims.

5. How can competitors challenge a patent like AU2015200149?

   They can contest validity through prior art submissions for lack of novelty or inventive step or challenge the patent's scope during opposition proceedings.

---

References

[1] Australian Patent Office. (2022). Guide to patent law in Australia. Retrieved from https://www.ipaustralia.gov.au

[2] World Intellectual Property Organization. (2022). Patent Landscape Reports. https://www.wipo.int/portal/en/index.html

[3] Australian Patents Act 1990 (Cth). Retrieved from https://www.legislation.gov.au/Series/C2004A04162